Abbott Laboratories
Sector unknown·ABT · USA (SEC 10-K)·Fiscal year to 31/12/2025
Reportable Segments Manufacturing Sites Medical Devices 33 Diagnostic Products 21 Established Pharmaceutical Products 22 Nutritional Products 13 Worldwide Total 89 Abbott’s research and development facilities in the United States are primarily located in California, Illinois, Minnesota, New Jersey, and Ohio.
Exposure profile
Derived from what the company itself writes. Empty directions mean the report doesn't mention themes of that type.
In their own words
Grouped by theme, from the management review in the annual report. A · The company itself is a verbatim quote, B · From the report is without a verified quote.
Biotech and drug development
Technology
Market
“Reportable Segments Manufacturing Sites Medical Devices 33 Diagnostic Products 21 Established Pharmaceutical Products 22 Nutritional Products 13 Worldwide Total 89 Abbott’s research and development facilities in the United States are primarily located in California, Illinois, Minnesota, New Jersey, and Ohio.”
Annual report 2025A · The company itself
Chains in: US drug pricing policy mixed effect, Patent expiry and generic competition weakens, Drug approvals strengthens
Chains out: this strengthens Buying contract manufacturing and research (CMO/CRO/EMS), strengthens Contract manufacturers as a business (EMS, CMO, CRO)
Diabetes care
Technology
Market
“Reportable Segments Manufacturing Sites Medical Devices 33 Diagnostic Products 21 Established Pharmaceutical Products 22 Nutritional Products 13 Worldwide Total 89 Abbott’s research and development facilities in the United States are primarily located in California, Illinois, Minnesota, New Jersey, and Ohio.”
Annual report 2025A · The company itself
Media and entertainment
End markets
Market
“Reportable Segments Manufacturing Sites Medical Devices 33 Diagnostic Products 21 Established Pharmaceutical Products 22 Nutritional Products 13 Worldwide Total 89 Abbott’s research and development facilities in the United States are primarily located in California, Illinois, Minnesota, New Jersey, and Ohio.”
Annual report 2025A · The company itself
Medical devices
Technology
Market
“Reportable Segments Manufacturing Sites Medical Devices 33 Diagnostic Products 21 Established Pharmaceutical Products 22 Nutritional Products 13 Worldwide Total 89 Abbott’s research and development facilities in the United States are primarily located in California, Illinois, Minnesota, New Jersey, and Ohio.”
Annual report 2025A · The company itself
Chains in: Ageing population strengthens
Competitors mentioned in the report
No named competitors in the report.
Financial figures
| Revenue latest fiscal year | 44.33 bn USD |
| Revenue growth vs. the year before, same method | 5.7 % |
| EBITDA reported by the company | 11.17 bn USD |
| Net debt debt incl. leasing minus cash | 5.61 bn USD |
| Diluted EPS per share | 3.72 USD |
Source: 10-K (SEC) A. See the report
Criteria
| Profit | ✓ |
| Growing | ✓ |
| Healthy balance sheet | ✓ |
Only the criteria that can be computed from financial statements on this page. The remaining criteria (such as price and dividend) need a share price and are in the analysis.
Figures are in the report's currency (USD), not converted to DKK. Quotes are shown as the company's own words in English.